MX2012000766A - Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. - Google Patents

Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Info

Publication number
MX2012000766A
MX2012000766A MX2012000766A MX2012000766A MX2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A
Authority
MX
Mexico
Prior art keywords
compound
erythropoietin production
prolyl hydroxylase
action
hydroxylase inhibitor
Prior art date
Application number
MX2012000766A
Other languages
English (en)
Spanish (es)
Inventor
Takashi Ito
Masahiro Yokota
Kazuhito Ueyama
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masakazu Terashita
Dai Motoda
Takahiro Hotta
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2012000766A publication Critical patent/MX2012000766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
MX2012000766A 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. MX2012000766A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
MX2012000766A true MX2012000766A (es) 2012-02-08

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000766A MX2012000766A (es) 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Country Status (28)

Country Link
US (3) US8283465B2 (enExample)
EP (3) EP2455381B9 (enExample)
JP (9) JP5021797B2 (enExample)
KR (4) KR20230165366A (enExample)
CN (1) CN102471337B (enExample)
AR (1) AR077417A1 (enExample)
AU (1) AU2010271732B2 (enExample)
BR (1) BR112012001157A2 (enExample)
CA (1) CA2768505C (enExample)
CO (1) CO6430426A2 (enExample)
DK (1) DK2455381T5 (enExample)
ES (1) ES2477968T3 (enExample)
HR (1) HRP20140705T1 (enExample)
IL (1) IL217541A (enExample)
ME (1) ME01858B (enExample)
MX (1) MX2012000766A (enExample)
MY (1) MY160814A (enExample)
NZ (1) NZ598242A (enExample)
PE (1) PE20120629A1 (enExample)
PL (1) PL2455381T3 (enExample)
PT (1) PT2455381E (enExample)
RS (1) RS53499B1 (enExample)
RU (1) RU2538963C2 (enExample)
SG (1) SG178049A1 (enExample)
SI (1) SI2455381T1 (enExample)
SM (1) SMT201500122B (enExample)
TW (1) TWI485150B (enExample)
WO (1) WO2011007856A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2014080640A1 (ja) 2012-11-26 2014-05-30 国立大学法人東北大学 エリスロポエチン発現増強剤
EA028402B1 (ru) 2012-12-24 2017-11-30 Кадила Хелзкэр Лимитед Хинолоновые производные
CA2914662C (en) 2013-06-13 2022-05-31 Robert Shalwitz Compositions and methods for treating anemia
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
PT3052096T (pt) * 2013-10-03 2018-04-04 Kura Oncology Inc Inibidores de erk e métodos de utilização
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
EP3305293A4 (en) * 2015-05-28 2019-01-16 Japan Tobacco Inc. METHOD FOR THE TREATMENT OR PREVENTION OF NEPHROPATHIA DIABETICA
CN110214139B (zh) * 2016-11-25 2022-08-23 日本烟草产业株式会社 用于生产三唑并吡啶化合物的方法
CA3062972C (en) 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine
BR112020004857A2 (pt) * 2017-10-04 2020-09-15 Japan Tobacco, Inc. composto heteroarila contendo hidrogênio, e uso farmacêutico do mesmo
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
FI3808747T3 (fi) * 2018-09-13 2025-02-07 Kissei Pharmaceutical Imidatsopyridinoniyhdiste
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
KR20220152276A (ko) * 2020-03-11 2022-11-15 깃세이 야쿠힌 고교 가부시키가이샤 이미다조피리디논 화합물 또는 그 염의 결정
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269B (zh) * 2021-12-02 2025-02-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
TW202412778A (zh) * 2022-09-19 2024-04-01 大陸商蘇中藥業集團股份有限公司 一種脯氨醯羥化酶抑制劑及其用途
WO2024245389A1 (zh) * 2023-06-02 2024-12-05 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
TW202506675A (zh) * 2023-08-08 2025-02-16 美商富曼西公司 用於防治和對抗無脊椎有害生物的連接的雙環化合物
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
WO2025137158A1 (en) * 2023-12-19 2025-06-26 Akebia Therapeutics, Inc. Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use
CN119700755A (zh) * 2024-02-05 2025-03-28 深圳信立泰药业股份有限公司 化合物在制备预防和/或治疗高原病的药物中的应用
CN119818492A (zh) * 2024-02-05 2025-04-15 深圳信立泰药业股份有限公司 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
CN119039291A (zh) * 2024-09-09 2024-11-29 南京药坦生物科技有限公司 一种恩那度司他中间体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
MXPA04003277A (es) * 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
MX2007001431A (es) * 2004-08-05 2007-04-02 Hoffmann La Roche Derivados de indol, de indazol o de indolina.
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
US7811595B2 (en) * 2006-06-26 2010-10-12 Warner Chilcott Company, Llc Prolyl hydroxylase inhibitors and methods of use
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
JP2010524942A (ja) * 2007-04-18 2010-07-22 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
AU2008331480A1 (en) * 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EA201000920A1 (ru) * 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
JP2011519858A (ja) 2008-04-30 2011-07-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラ−ゼ阻害剤
EP2297144A1 (en) 2008-05-29 2011-03-23 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
CN102317287B (zh) 2008-12-19 2014-10-08 利奥制药有限公司 作为磷酸二酯酶抑制剂、用于治疗皮肤病的三唑并吡啶化合物
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina

Also Published As

Publication number Publication date
JP6434575B2 (ja) 2018-12-05
EP2455381B1 (en) 2014-05-28
CO6430426A2 (es) 2012-04-30
JP5021797B2 (ja) 2012-09-12
SG178049A1 (en) 2012-03-29
JP2022126843A (ja) 2022-08-30
CN102471337A (zh) 2012-05-23
US8283465B2 (en) 2012-10-09
KR20230165366A (ko) 2023-12-05
JP2019019144A (ja) 2019-02-07
AR077417A1 (es) 2011-08-24
NZ598242A (en) 2013-09-27
EP2455381A4 (en) 2012-12-12
PT2455381E (pt) 2014-06-24
HRP20140705T1 (hr) 2014-09-12
JP2012144571A (ja) 2012-08-02
JP2024091878A (ja) 2024-07-05
BR112012001157A2 (pt) 2016-02-23
TWI485150B (zh) 2015-05-21
JP2015003933A (ja) 2015-01-08
US20110077267A1 (en) 2011-03-31
HK1168346A1 (en) 2012-12-28
CA2768505A1 (en) 2011-01-20
JP2017214404A (ja) 2017-12-07
JP2020111612A (ja) 2020-07-27
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
KR101850661B1 (ko) 2018-04-19
US20160145254A1 (en) 2016-05-26
TW201105671A (en) 2011-02-16
KR101706803B1 (ko) 2017-02-14
CN102471337B (zh) 2014-12-10
KR20180042443A (ko) 2018-04-25
PL2455381T3 (pl) 2014-10-31
WO2011007856A1 (ja) 2011-01-20
RS53499B1 (sr) 2015-02-27
RU2012105467A (ru) 2013-08-27
PE20120629A1 (es) 2012-05-30
ME01858B (me) 2014-12-20
ES2477968T9 (es) 2014-11-13
SMT201500122B (it) 2015-07-09
AU2010271732A1 (en) 2012-03-08
EP2746282A1 (en) 2014-06-25
JP2016040321A (ja) 2016-03-24
EP3594213A1 (en) 2020-01-15
DK2455381T3 (da) 2014-07-21
EP2455381B9 (en) 2014-10-22
US20130096155A1 (en) 2013-04-18
DK2455381T5 (en) 2015-02-09
SI2455381T1 (sl) 2014-08-29
IL217541A (en) 2014-07-31
EP2455381A1 (en) 2012-05-23
RU2538963C2 (ru) 2015-01-10
AU2010271732B2 (en) 2016-08-25
KR20170018105A (ko) 2017-02-15
CA2768505C (en) 2018-06-12
JP2011037841A (ja) 2011-02-24
MY160814A (en) 2017-03-31
KR20120051704A (ko) 2012-05-22

Similar Documents

Publication Publication Date Title
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
AU2012214029A8 (en) Rorgammat inhibitors
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
WO2008011131A3 (en) Amide compounds
WO2008011130A8 (en) Amide compounds
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PH12013502677A1 (en) Benzylamine derivatives as inhibitors of plasma kallikrein
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
TN2012000092A1 (en) Therapeutic agent for mood disorders
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
IN2012DN01273A (enExample)
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
TN2012000093A1 (en) Therapeutic agent for anxiety disorders

Legal Events

Date Code Title Description
FG Grant or registration